Intercept Pharmaceuticals, Inc. (ICPT) Given Average Recommendation of “Buy” by Brokerages

Shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) have received a consensus rating of “Buy” from the twenty brokerages that are currently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $188.67.

ICPT has been the topic of several research analyst reports. Laidlaw restated a “hold” rating and set a $119.00 target price (up from $115.00) on shares of Intercept Pharmaceuticals in a report on Tuesday, August 1st. BMO Capital Markets raised their target price on shares of Intercept Pharmaceuticals from $218.00 to $221.00 and gave the stock an “outperform” rating in a report on Tuesday, August 1st. Cantor Fitzgerald set a $60.00 target price on shares of Intercept Pharmaceuticals and gave the stock a “sell” rating in a report on Thursday, May 4th. BidaskClub downgraded shares of Intercept Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, August 4th. Finally, Wedbush restated an “outperform” rating and set a $231.00 target price on shares of Intercept Pharmaceuticals in a report on Friday, May 26th.

In related news, Director Daniel G. Welch sold 217 shares of the firm’s stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $126.76, for a total value of $27,506.92. Following the completion of the transaction, the director now directly owns 3,710 shares of the company’s stock, valued at $470,279.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Mark Pruzanski sold 40,000 shares of the firm’s stock in a transaction on Monday, June 26th. The shares were sold at an average price of $130.80, for a total transaction of $5,232,000.00. Following the completion of the transaction, the chief executive officer now directly owns 611,718 shares of the company’s stock, valued at $80,012,714.40. The disclosure for this sale can be found here. Insiders sold 47,575 shares of company stock valued at $6,144,469 over the last three months. 9.20% of the stock is owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. boosted its position in Intercept Pharmaceuticals by 0.7% in the first quarter. PNC Financial Services Group Inc. now owns 2,020 shares of the biopharmaceutical company’s stock worth $229,000 after buying an additional 14 shares during the period. Public Employees Retirement Association of Colorado boosted its position in Intercept Pharmaceuticals by 1.1% in the second quarter. Public Employees Retirement Association of Colorado now owns 4,111 shares of the biopharmaceutical company’s stock worth $498,000 after buying an additional 43 shares during the period. Janney Montgomery Scott LLC boosted its position in Intercept Pharmaceuticals by 1.8% in the second quarter. Janney Montgomery Scott LLC now owns 3,435 shares of the biopharmaceutical company’s stock worth $416,000 after buying an additional 62 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Intercept Pharmaceuticals by 14.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 132 shares during the period. Finally, Oppenheimer & Co. Inc. boosted its position in Intercept Pharmaceuticals by 9.0% in the first quarter. Oppenheimer & Co. Inc. now owns 2,152 shares of the biopharmaceutical company’s stock worth $244,000 after buying an additional 178 shares during the period. 83.93% of the stock is owned by hedge funds and other institutional investors.

Intercept Pharmaceuticals (NASDAQ:ICPT) opened at 101.12 on Monday. Intercept Pharmaceuticals has a 12 month low of $96.63 and a 12 month high of $172.95. The stock’s market capitalization is $2.54 billion. The company’s 50-day moving average is $121.60 and its 200-day moving average is $117.79.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its earnings results on Monday, July 31st. The biopharmaceutical company reported ($3.46) EPS for the quarter, topping the consensus estimate of ($3.62) by $0.16. The firm had revenue of $30.89 million for the quarter, compared to the consensus estimate of $27.50 million. Intercept Pharmaceuticals had a negative net margin of 543.35% and a negative return on equity of 135.24%. The business’s quarterly revenue was up 459.6% on a year-over-year basis. During the same period last year, the company posted ($3.14) EPS. Equities analysts anticipate that Intercept Pharmaceuticals will post ($14.05) earnings per share for the current year.

WARNING: “Intercept Pharmaceuticals, Inc. (ICPT) Given Average Recommendation of “Buy” by Brokerages” was published by BNB Daily and is the property of of BNB Daily. If you are reading this piece on another site, it was stolen and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.baseball-news-blog.com/2017/08/19/intercept-pharmaceuticals-inc-icpt-receives-average-rating-of-buy-from-brokerages-updated-updated-updated.html.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply